Profiling the endocannabinoid response to hedonic eating

Published: 23-04-2015
Last updated: 21-04-2024

The primary objective is to assess changes in endocannabinoid plasma levels prior, during and after eating of hedonically liked versus non-pleasurable foods.

Ethical review	Approved WMO
Status	Recruitment stopped
Health condition type	Other condition
Study type	Interventional

Summary

ID

NL-OMON42088

Source
ToetsingOnline

Brief title
Cravings

Condition

- Other condition
- Appetite and general nutritional disorders

Synonym
Obesity, overweight

Health condition

Obesitas

Research involving
Human

Sponsors and support

Primary sponsor: Wageningen Universiteit
Source(s) of monetary or material Support: Ministerie van OC&W

Intervention

Keyword: Endocannabinoïd system, Hedonic eating

Outcome measures

Primary outcome

The endocannabinoid plasma profile prior, during and after eating of a

hedonically liked food product compared to a non-pleasurable food product.

Secondary outcome

- plasma levels of ghrelin, GLP1, PP, FFA, glucose and insulin prior, during

and after eating of a hedonically liked food product compared to a

non-pleasurable food product.

- the correlation between eCB profile and FFA profile.

- hunger ratings prior and after eating of a hedonically liked food product

compared to a non-pleasurable food product.

Study description

Background summary

The endocannabinoid system has been found to be involved in hedonic eating, but as of yet it is unknown during what phase(s) of eating, i.e., if the endocannabinoid system is involved during anticipation and consumption of food and satiety.

Study objective

The primary objective is to assess changes in endocannabinoid plasma levels prior, during and after eating of hedonically liked versus non-pleasurable

foods.

Study design

The study has a randomized, cross-over design. In two different sessions subjects will receive either hedonically pleasant brownie or non-pleasurable brownie. The two test sessions are at least two weeks apart.

Intervention

NA

Study burden and risks

The study will consist of an intake session that takes 45 minutes, and two test sessions of approximately 4.5 hours per session on separate days, giving a total of approximately 10 hours. The study is non-therapeutic for participants. During each session an intravenous cannula will be inserted and used for blood drawing, this may cause some discomfort for the participants. The Hb value of each participants will be determined before participation, blood collection will therefore not lead to anaemia. Participants will receive their evening meal and breakfast prior to each test session.

Contacts

Public
Wageningen Universiteit

Bomenweg 2
Wageningen 6703 HD
NL
Scientific
Wageningen Universiteit

Bomenweg 2
Wageningen 6703 HD
NL

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age
Adults (18-64 years)
Elderly (65 years and older)

Inclusion criteria

Male
Healthy
Age: 18-35 years
BMI: 18.5-25 kg/m2

Exclusion criteria

Being allergic for products under study
Not consuming products under study for lifestyle reasons
Endocrine disorder
Use of medication that may influence study outcomes
Smoking >1 cigarette per day
Consuming more than 21 units of alcohol per week
Using cannabis more than 12 times per year
Recent blood donation(<1 month prior to the first test session)

Study design

Design

Study type:	Interventional
Intervention model:	Crossover
Masking:	Open (masking not used)
Control:	Uncontrolled
Primary purpose:	Basic science

Recruitment

NL

Recruitment status:	Recruitment stopped
Start date (anticipated):	27-08-2015
Enrollment:	25
Type:	Actual

Ethics review

Approved WMO Date:	23-04-2015
Application type:	First submission
Review commission:	METC Wageningen Universiteit (Wageningen)
Approved WMO Date:	15-09-2015
Application type:	Amendment
Review commission:	METC Wageningen Universiteit (Wageningen)

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register	ID
CCMO	NL51830.081.14